Abiopharma

New Form EFFECT - CRESCENT BIOPHARMA, INC. Filed: 2026-01-15 AccNo: 9999999995-26-000182 Size: 1 KB

New Form EFFECT - Canopy Growth Corp Filed: 2026-01-15 AccNo: 9999999995-26-000184 Size: 1 KB

Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

New Form 3 - CorMedix Inc. Filed: 2026-01-15 AccNo: 0001213900-26-004855 Size: 11 KB

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Seckler Michael David 🟢 acquired 133.2K shares of CorMedix Inc. (CRMD) Transaction Date: Jan 08, 2026 | Filing ID: 004857

Kovacs Shane William Charles 🔴 sold 103.8K shares of Olema Pharmaceuticals, Inc. (OLMA) at $28.73 ($3.0M) Transaction Date: Jan 13, 2026 | Filing ID: 000002

Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA

アジーナス、BOT+BALを推進し、米国での製造体制を強化するため、ザイダス・ライフサイエンスとの1億4100万ドル規模の戦略的提携を締結

Agenus anuncia el cierre de una colaboración estratégica por un valor de USD 141 millones con Zydus Lifesciences para impulsar BOT+BAL y reforzar la preparación de la fabricación en EE. UU.